Russian version English version
About the Journal
Editorial Board
Instructions for Authors
Information for Readers and Authors
Current Issue
Archive
Contact Us
Search

Send manuscript
 


Volume 14   Issue 1   Year 2019
Kiselev I.N.1,2, Kutumova E.O.1,2, Kolpakova A.F.1,2, Lifshits G.I.3, Kolpakov F.A.1,2

Mathematical Modeling of the Antihypertensive Drugs Action

Mathematical Biology & Bioinformatics. 2019;14(1):233-256.

doi: 10.17537/2019.14.233.

References

 

  1. Chazova I.E., Oshepkova E.V., Zhernakova Yu.V., Karpov Yu.A., Arkhipov M.V., Barbarash O.L., Galyavich A.S., Grinshtein Yu.I., Eregin S.Ya., Karpov R.S. et al. Clinical guidelines Diagnostics and treatment of arterial hypertension. Kardiologicheskii Vestnik (Russian Cardiology Bulletin). 2015;10(1):3–30 (in Russ.).
  2. Global brief on hypertension. World Health Organization, 2014. 40 p. https://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/ (accessed 29.05.2019).
  3. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365:217–223. doi: 10.1016/S0140-6736(05)70151-3
  4. Irazola V.E., Gutierrez L., Bloomfield G., Carrillo-Larco R.M., Dorairaj P., Gaziano T., Levitt N.S., Miranda J.J., Ortiz A.B., Steyn K., Wu Y., Xavier D., Yan L.L., He J., Rubinstein A. Hypertension Prevalence, Awareness, Treatment, and Control in Selected LMIC Communities: Results From the NHLBI/UHG Network of Centers of Excellence for Chronic Diseases. Global Heart. 2016;11(1):47–59. doi: 10.1016/j.gheart.2015.12.008
  5. Boytsov S.A., Balanova Yu.A., Shalnova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M., Duplyakov D.V., Efanov A.Yu., Zhernakova Yu.V., Konradi A.O. et al. Arterial hypertension among individuals of 25–64 years old: Prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4–14 (in Russ.).
  6. Rapsomaniki E., Timmis A., George J., Pujades-Rodriguez M., Shah A.D., Denaxas S.C., White I.R., Caulfield M.J., Deanfield J.E., Smeeth L., Williams B.P., Hingorani A.D., Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. The Lancet. 2014;383(9932):1899–1911. doi: 10.1016/S0140-6736(14)60685-1
  7. Ehret G.B. Genome-Wide Association Studies: Contribution of Genomics to Understanding Blood Pressure and Essential Hypertension. Current Hypertension Reports. 2010;12(1):17–25. doi: 10.1007/s11906-009-0086-6
  8. Shih P.B., O’Connor D.T. Hereditary Determinants of Human Hypertension. Strategies in the Setting of Genetic Complexity. Hypertension. 2008;51(6):1456–1464. doi: 10.1161/HYPERTENSIONAHA.107.090480
  9. Cornelissen V.A., Fagard R.H., Coeckelberghs E., Vanhees L. Impact of Resistance Training on Blood Pressure and Other Cardiovascular Risk Factors A Meta-Analysis of Randomized, Controlled Trials. Hypertension. 2011;58(5):950–958. doi: 10.1161/HYPERTENSIONAHA.111.177071
  10. Sistema krovoobrashcheniia i arterial'naia gipertoniia: biofizicheskie i genetiko-fiziologicheskie mekhanizmy, matematicheskoe i komp'iuternoe modelirovanie (Cardiovascular System and Arterial Hypertension: Biophysical, Genetic and Physiological Mechanisms, Mathematical and Computer Modeling). Eds. L.N. Ivanova, A.M. Blokhin, A.L. Markel. Novosibirsk: Publishing House of the Siberian Branch of the Russian Academy of Sciences, 2008 (in Russ.).
  11. Oparil S., Acelajado M.C., Bakris G.L., Berlowitz D.R., Cífková R., Dominiczak A.F., Grassi G., Jordan J., Poulter N.R., Rodgers A., Whelton P.K. Hypertension. Nature Reviews Disease Primers. 2018;4:18014. doi: 10.1038/nrdp.2018.14
  12. Campbell N.R., Lackland D.T., Niebylski M.L. High blood pressure: why prevention and control are urgent and important: a 2014 fact sheet from the World Hypertension League and the International Society of Hypertension. The Journal of Clinical Hypertension. 2014;16(8):551–553. doi: 10.1111/jch.12372
  13. Lebedev A.A. Renin-Angiotensin System. Soros Educational Journal. 1998;3:35–40 (in Russ.).
  14. Sethi A.A., Nordestgaard B.G., Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a metaanalysis. Arterioscler. Tromb. Vasc. Biol. 2003;7(23):1269–1275.
  15. Kiselev I.N., Semisalov B.V., Biberdorf E.A., Sharipov R.N., Blokhin A.M., Kolpakov F.A. Modular Modeling of the Human Cardiovascular System. Mathematical Biology and Bioinformatics. 2012;7(2):703–736 (in Russ.). doi: 10.17537/2012.7.703
  16. Kiselev I.N., Biberdorf E.A., Baranov V.I., Komlyagina T.G., Melnikov V.N., Suvorova I.Yu., Krivoshchekov S.G., Kolpakov F.A. Personalization of Parameters and Validation of Model of the Human Cardiovascular System. Mathematical Biology and Bioinformatics. 2015;10(2):526–547 (in Russ.). doi: 10.17537/2015.10.526
  17. Kolpakova A.F. Prospects for the use of direct renin inhibitor aliskiren for the treatment of socially significant diseases. The Siberian Medical Journal. 2014;29(2):14–21 (in Russ.).
  18. Gradman A.H., Schmieder R.E., Lins R.L., Nussberger J., Chiang Y., Bedigian M.P. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–1018. doi: 10.1161/01.CIR.0000156466.02908.ED
  19. Sica D.A., Gehr T.W., Ghosh S. Clinical Pharmacokinetics of Losartan. Clinical Pharmacokinetics. 2005;44(8):797–814. doi: 10.2165/00003088-200544080-00003
  20. Steinmann E., Pfisterer M., Burkart F. Acute hemodynamic effects of bisoprolol, a new beta 1 selective adrenoreceptor blocking agent, in patients with coronary artery disease. Journal of Cardiovascular Pharmacology. 1986;8(5):1044–1050. doi: 10.1097/00005344-198609000-00024
  21. Ferguson R.K., Vlasses P.H., Swanson B.N., Mojaverian P., Hichens M., Irvin J.D., Huber P.B. Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clinical Pharmacology and Therapeutics. 1982;32(1):48–53. doi: 10.1038/clpt.1982.125
  22. Faulkner J.K., McGibney D., Chasseaud L.F., Perry J.L., Taylor I.W. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. British Journal of Clinical Pharmacology. 1986;22:21–25. doi: 10.1111/j.1365-2125.1986.tb02874.x
  23. Proshin A.P., Solodyannikov Yu.V. Mathematical modeling of blood circulation system and its practical application. Automation and Remote Control. 2006;67(2):329-341. doi: 10.1134/S000511790602010X
  24. Karaaslan F., Denizhan Y., Kayserilioglu A., Ozcan Gulcur H. Long-term mathematical model involving renal sympathetic nerve activity, arterial pressure, and sodium excretion. Annals of Biomedical Engineering. 2005;33(11):1607–1630. doi: 10.1007/s10439-005-5976-4
  25. Hallow K.M., Lo A., Beh J., Rodrigo M., Ermakov S., Friedman S., de Leon H., Sarkar A., Xiong Y., Sarangapani R., Schmidt H., Webb R., Kondic A.G. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: Extending the Guyton model. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2014;306(9):R647–R662. doi: 10.1152/ajpregu.00039.2013
  26. Hindmarsh A.C., Brown P.N., Grant K.E., Lee S.L., Serban R., Shumaker, D.E., Woodward C.S. SUNDIALS: Suite of Nonlinear and Differential/Algebraic Equation Solvers. ACM Transactions on Mathematical Software. 2005;31(3):363–396. doi: 10.1145/1089014.1089020
  27. Hong Y., Dingemanse J., Mager D.E. Pharmacokinetic/Pharmacodynamics modeling of renin biomarkers in subjects treated with the renin inhibitor Aliskiren. Clinical Pharmacology Therapeutics. 2008;84(1):136–143. doi: 10.1038/sj.clpt.6100495
  28. Bonate P.L. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer, 2006. 387 p.
  29. Intensivnaia terapiia. Natsional'noe rukovodstvo (Cochrane Database of Systematic Reviews. Intensive therapy. National manual). Vol. 2. Eds. Gel'fand B.R., Saltanov A.I. Moscow, 2011.
  30. Heran B.S., Wong M.M., Heran I.K., Wright J.M. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews. 2008;4. Article No. CD003822. doi: 10.1002/14651858.CD003822.pub2
  31. Lithell H., Selinus I., Hosie J., Frithz G., Weiner L. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. European Heart Journal. 1987;8:55–64. doi: 10.1093/eurheartj/8.suppl_M.55-a
  32. Hayashi K., Wakino S., Sugano N., Ozawa Y., Homma K., Saruta T. Ca2+ Channel Subtypes and Pharmacology in the Kidney. Circulation Research. 2007;100(3):342–353. doi: 10.1161/01.RES.0000256155.31133.49
  33. Mel'nikov V.N., Komliagina T.G., Rechkina S.Iu., Lazareva I.F., Suvorova I.Iu., Krivoshchekov S.G. Pokazateli elastichnosti arterii i gemodinamiki u zdorovykh i bol'nykh liudei (Indicators of arterial elasticity and hemodynamics in healthy and sick people): a database registered in the Register of databases of the Federal Service for Intellectual Property No. 2012620540. 2012 (in Russ.).
  34. Pruett W.A., Husband L.D., Husband G., Dakhlalla M., Bellamy K., Coleman T.G., Hester R.L. A population Model of Integrative Cardiovascular physiology. PLoS One. 2013;8(9). doi: 10.1371/journal.pone.0074329
  35. Kiselev I.N., Sharipov R.N., Mandrik N.V., Kolpakov F.A. Population-based modeling of the human cardiovascular system in biouml platform. In: Proceedings of the XVI All-Russian Conference DICR-2017. Novosibirsk, 2017. P. 212–217 (in Russ.). http://elib.ict.nsc.ru/jspui/handle/ICT/1467 (accessed 29.05.2019).
  36. Gibson J.G., Evans W.A. Clinical studies of the blood volume. II. The relation of plasma and total blood volume to venous pressure, blood velocity rate, physical measurements, age and sex in NINETY normal humans. The Journal of Clinical Investigation. 1937;16(3):317–328. doi: 10.1172/JCI100860
  37. Teregulov Y.E. Integrated indicators of the central haemodynamics at healthy persons and patients with a hypertension depending on haemodynamics type. Practical medicine. 2012;2(8(64-2)):164–168 (in Russ.).
  38. Kazakova M.S., Lugovskaya S.A., Dolgov V.V. The reference values of indicators of total blood analysis of adult working population. Russian Clinical Laboratory Diagnostics. 2012(6):43–49 (in Russ.).
  39. Payne R.B., Levell M.J. Redefinition of the normal range for serum sodium. Clinical Chemistry. 1968;14(2):172–178.
  40. Rastegar A. Chapter 195. Serum Potassium. In: Clinical methods: The history, physical, and laboratory examinations. 3rd edition. Eds. Walker H.K., Hall W.D., Hurst J.W. Boston: Butterworths, 1990.
  41. Smirnov A.V., Shilov E.M., Dobronravov V.A., Kayukov I.G., Bobkova I.N., Shvetsov M.Y., Tsygin A.N., Shutov A.M. National guidelines. chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nephrology (Saint-Petersburg). 2012;16(1):89–115 (in Russ.).
  42. Bertram J.F., Douglas-Denton R.N., Diouf B., Hughson M.D., Hoy W.E. Human nephron number: implications for health and disease. Pediatric Nephrology. 2011;26:1529–1533. doi: 10.1007/s00467-011-1843-8
  43. Hoy W.E., Ingelfinger J.R., Hallan S., Hughson M.D., Mott S.A., Bertram J.F. The early development of the kidney and implications for future health. Journal of Developmental Origins of Health and Disease. 2010;1(4):216–233. doi: 10.1017/S204017441000022X
  44. Hoy W.E., Douglas-Denton R.N., Hughson M.D., Cass A., Johnson K., Bertram J.F. A stereological study of glomerular number and volume: preliminary findings in a multiracial study of kidneys at autopsy. Kidney International Supplements. 2003;63(83):S31–S37. doi: 10.1046/j.1523-1755.63.s83.8.x
  45. Nozuki M., Mouri T., Itoi K., Takahashi K., Totsune K., Saito T., Yoshinaga K. Plasma concentrations of atrial natriuretic peptide in various diseases. The Tohoku Journal of Experimental Medicine. 1986;148:439–447. doi: 10.1620/tjem.148.439
  46. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., Picard M.H., Roman M.J., Seward J., Shanewise J. et al. Recommendations for chamber quantification. Eur. J. Echocardiogr. 2006;7(2):79–108. doi: 10.1016/j.euje.2005.12.014
  47. Hudsmith L.E., Petersen S.E., Francis J.M., Robson M.D., Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. Journal of Cardiovascular Magnetic Resonance. 2005;7:775–782. doi: 10.1080/10976640500295516
  48. Mel'nik A.A. Medical newspaper "Health of Ukraine". 2017. No. 19 (416) (in Ukrainian).
  49. Valabhji J., Donovan J., Kyd P.A., Schachter M., Elkeles R.S. The relationship between active renin concentration and plasma renin activity in Type 1 diabetes. Diabetic Medicine. 2001;18:451–458. doi: 10.1046/j.1464-5491.2001.00489.x
  50. Nussberger J., Brunner D., Keller I., Brunner H.R. Measurement of converting enzyme activity by antibody-trapping of generatedangiotensin II. Comparison with two other methods. American Journal of Hypertension. 1992;5:393–398. doi: 10.1093/ajh/5.6.393
  51. Akhadov S.V., Ruzbanova G.R., Molchanova G.S., Talalaeva T.G., Khoreva S.N. Target levels of renin-angiotensin-aldosterone system components and their role in cardiovascular event development among patients with arterial hypertension. Russian Journal of Cardiology. 2009;3(77):26–32 (in Russ.).
  52. Brown M.J., McInnes G.T., Papst C.C., Zhang J., MacDonald T.M. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. The Lancet. 2011;377:312–320. doi: 10.1016/S0140-6736(10)62003-X
  53. Kwakernaak A.J., Roksnoer L.C., Lambers Heerspink H.J., van den Berg-Garrelds I., Lochorn G.A., van Embden Andres J.H., Klijn M.A., Kobori H., Danser A.H., Laverman G.D., Navis G.J. Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial. PLoS One. 2017;12(1) Article No. e0169258. doi: 10.1371/journal.pone.0169258
  54. Porthan K., Viitasalo M., Hiltunen T.P., Väänänen H., Dabek J., Suonsyrjä T., Hannila-Handelberg T., Virolainen J., Nieminen M.S., Toivonen L., Kontula K., Oikarinen L. Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Annals of Medicine. 2009;41(1):29–37. doi: 10.1080/07853890802195211
  55. Nedogoda S.V., Ledyaeva A.A., Chumachok E.V., Tsoma V.V., Mazina G., Salasyuk A.S., Barykina I.N. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clinical Drug Investigation. 2013;33(8):553–561. doi: 10.1007/s40261-013-0094-9
  56. Oparil S., Barr E., Elkins M., Liss C., Vrecenak A., Edelman J. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clinical Therapeutics. 1996;18(4):608–625. doi: 10.1016/S0149-2918(96)80212-8
  57. Martina B., Dieterle T., Weinbacher M., Battegay E. Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology. 1999;92(2):110–114. doi: 10.1159/000006957
  58. Lee S.E., Kim Y.J., Lee H.Y., Yang H.M., Park C.G., Kim J.J., Kim S.K., Rhee M.Y., Oh B.H. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clinical Therapeutics. 2012;34(3):552–568. doi: 10.1016/j.clinthera.2012.01.024
  59. Oparil S., Abate N., Chen E., Creager M.A., Galet V., Jia G., Julius S., Lerman A., Lyle P.A., Pool J., Tershakovec A.M. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. Current Medical Research and Opinion. 2008;24(4):1101–1114. doi: 10.1185/030079908X280716
  60. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Pressure. 2007;16(2):7–12. doi: 10.1080/08038020701561687
  61. Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. American Journal of Cardiology. 1991;68:61–64. doi: 10.1016/0002-9149(91)90711-S
  62. Amabile G., Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. European Heart Journal. 1987;8:65–69. doi: 10.1093/eurheartj/8.suppl_M.65
  63. Honore P. Bisoprolol versus hydrochlorothiazide plus amiloride in essential hypertension, a randomized double-blind study. European Heart Journal. 1987;8:95–102. doi: 10.1093/eurheartj/8.suppl_M.95
  64. Mengden T., Bättig B., Schubert M., Jeck T., Weisser B., Buddeberg C., Vetter W. Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol. European Journal of Clinical Pharmacology. 1992;42(6):569–576. doi: 10.1007/BF00265917
  65. Puig J.G., Calvo C., Luurila O., Luurila H., Sulosaari S., Strandberg A., Ghezzi C. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. Journal of Human Hypertension. 2007;21(12):917–924. doi: 10.1038/sj.jhh.1002248
  66. Mallion J.M. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Pressure. 2007;16(2):13–18.
  67. Agabiti Rosei E., Morelli P., Rizzoni D. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild–moderate hypertension. Blood Pressure. 2005;14(1):14–22. doi: 10.1080/08037050510034257
  68. Fagher B., Henningsen N., Hulthén L., Katzman P., Thulin T. Antihypertensive and renal effects of enalapril and slow-release verapamil in essential hypertension. A double-blind, randomized study. European Journal of Clinical Pharmacology. 1990;39(1):S41–S43. doi: 10.1007/BF03216275
  69. Fermé I., Djian J., Tcherdakoff P. Comparative study on monotherapy with sustained-release diltiazem 300 mg and enalapril 20 mg in mild to moderate arterial hypertension. Journal of Cardiovascular Pharmacology. 1990;16(1):S46–S50. doi: 10.1097/00005344-199000161-00009
  70. Corea L., Cardoni O., Fogari R., Innocenti P., Porcellati C., Provvidenza M., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clinical Pharmacology and Therapeutics. 1996;60(3):341–346. doi: 10.1016/S0009-9236(96)90061-2
  71. Tham T.C., Herity N., Guy S., Silke B. Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope. British Journal of Pharmacology. 1993;36(6):555–560.
  72. Parving H-H., Brenner B.M., McMurray J.V., Dick de Zeeuw, Steven M. Haffner, Solomon S.D., Chaturvedi N., Persson F., Desai A.S., Nicolaides M., Richard A., Xiang Z. et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. Engl. J. Med. 2012;367:2204–2213.
  73. Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat. Med. 2012;18(3):326. doi: 10.1038/nm0312-326
Table of Contents
Original Article
Math. Biol. Bioinf.
2019;14(1):233-256
doi: 10.17537/2019.14.233
published in Russian

Abstract (rus.)
Abstract (eng.)
Full text (rus., pdf)
References

 
  Copyright IMPB RAS © 2005-2024